Inulin and Acetate Production and Human Substrate Metabolism

Maastricht University Medical Centre (MUMC)

Status: Completed

Conditions: Obesity; Pre Diabetes

Treatments: Dietary Supplement: Inulin; Dietary Supplement: Placebo; Dietary Supplement: Inulin and Resistant Starch

Study type: Interventional

Funder types: Other

Identifiers

NCT03711383

NL63754.068.17

Details and patient eligibility

About

Based on our hypothesis that orally administered resistant starch and inulin/beta glucan will be fermented into a SCFA pattern high in acetate and that this will lead to beneficial effects on human substrate and energy metabolism, we aim to address the following primary objective:

To investigate the effects of an acute administration of inulin/beta glucan in combination with resistant starch on fecal and plasma acetate, as well as on fasting and postprandial substrate and energy metabolism in lean normoglycemic men and obese, prediabetic men.

Enrollment: 24 patients

Sex: Male

Ages: 30 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• lean (BMI ≥ 20kg/m2 and ≤ 24.9kg/m2)
• normoglycemic
• aged 30 - 65 years

OR

• overweight/obese (BMI ≥ 25kg/m2 and ≤ 34.9kg/m2)
• pre-diabetes
• aged between 30 - 65 years.

Exclusion criteria

• diabetes mellitus
• gastroenterological diseases or major abdominal surgery (allowed i.e.: - appendectomy, cholecystectomy)
• lactose intolerance and other digestive disorders
• cardiovascular disease, cancer, liver or kidney malfunction (determined -based on ALAT and creatinine levels, respectively)
• disease with a life expectancy shorter than 5 years
• Use of antibiotics 3 months prior inclusion
• Use of probiotics or prebiotics

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

24 participants in 3 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

isocaloric maltodextrin the day before CIDs

Treatment:

Dietary Supplement: Placebo

Inulin

Active Comparator group

Description:

12 g of inulin + isocaloric maltodextrin the day before CID

Treatment:

Dietary Supplement: Inulin

Inulin and Resistant Starch

Experimental group

Description:

12 g inulin + 7.5 g resistant starch the day before CID

Treatment:

Dietary Supplement: Inulin and Resistant Starch